Education
About Us
Working with TipRanks
Follow Us
MaxCyte Inc (GB:MXCT)
LSE:MXCT
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-8.18Last Year’s EPS
-6.94Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: -15.85%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
MaxCyte reported significant core revenue growth and strategic expansion with the acquisition of SeQure Dx and the expansion of its SPL portfolio. However, the company faced challenges with overall revenue decline and reduced instrument and SPL program-related revenues. While there were notable achievements, the financial setbacks present a balanced outlook.Company Guidance
During the call, MaxCyte provided guidance for 2025, projecting core revenue growth between 8% and 15%, inclusive of at least $2 million from their recent acquisition of SeQure Dx. The company expects SPL (Strategic Platform License) program-related revenue to be approximately $5 million, comprising pre-commercial milestone payments and commercial royalties. They ended 2024 with a total revenue of $38.6 million, marking a 6% decline from 2023, but core revenue increased by 9% to $32.5 million. MaxCyte aims to maintain gross margins in the low to mid-80s percentage range and anticipates ending 2025 with around $160 million in cash, cash equivalents, and investments. Although the macroeconomic environment remains challenging, MaxCyte is cautiously optimistic about potential improvements in the funding environment for their customers in 2025.Core Revenue Growth in 2024
MaxCyte reported core business revenue of $32.5 million for the full year 2024, representing a 9% increase from 2023. PA sales showed a very healthy revenue growth of 36% compared to 2023.
Strategic Acquisition of SeQure Dx
MaxCyte acquired SeQure Dx, enhancing its capabilities in safety assessment of cell and gene therapy development. The acquisition provides cross-selling opportunities and has been integrated successfully into MaxCyte's operations.
Expansion of SPL Portfolio
MaxCyte signed six new SPLs in 2024, increasing active SPL customers to 28, with 18 active clinical programs and one commercial program. The total pre-commercial milestone potential from these programs is greater than $220 million.
CASGEVY Progress
CASGEVY secured regulatory approvals in multiple countries and a reimbursement agreement with NHS England, expanding patient access globally. Approximately 50 patients have completed cell collection, up from about 30 in the previous quarter.
---
GB:MXCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:MXCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | 265.00p | 230.00p | -13.21% |
| Nov 06, 2024 | 303.00p | 279.00p | -7.92% |
| Aug 06, 2024 | 335.00p | 340.00p | +1.49% |
| May 07, 2024 | 290.00p | 395.00p | +36.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MaxCyte Inc (GB:MXCT) report earnings?
MaxCyte Inc (GB:MXCT) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is MaxCyte Inc (GB:MXCT) earnings time?
MaxCyte Inc (GB:MXCT) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of MaxCyte Inc stock?
The P/E ratio of MaxCyte is N/A.
What is GB:MXCT EPS forecast?
GB:MXCT EPS forecast for the fiscal quarter 2025 (Q1) is -8.18.
---